Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
Several other brokerages have also issued reports on CYTX. B. Riley reaffirmed a “buy” rating and set a $6.75 price objective on shares of Cytori Therapeutics in a report on Thursday, February 16th. Maxim Group raised their price objective on Cytori Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, February 15th.
Shares of Cytori Therapeutics (NASDAQ:CYTX) remained flat at $1.65 during trading on Monday. 34,863 shares of the stock traded hands. Cytori Therapeutics has a 12-month low of $1.36 and a 12-month high of $5.44. The stock’s market capitalization is $33.83 million. The firm’s 50-day moving average is $1.68 and its 200-day moving average is $1.74.
Your IP Address:
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 389,065 shares of the company’s stock after buying an additional 1,213 shares during the period. Perkins Capital Management Inc. owned 1.90% of Cytori Therapeutics worth $790,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.17% of the company’s stock.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.